Business Description
Medistim ASA
ISIN : NO0010159684
Total Employee Number:
159Compare
Compare
Traded in other countries / regions
MEDI.Norway0OCD.UKMEDIO.SwedenMD1.Germany IPO Date
2019-02-07Description
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.06 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.16 | |||||
Interest Coverage | 25.8 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 16.99 | |||||
Beneish M-Score | -2.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.9 | |||||
3-Year EBITDA Growth Rate | 11.9 | |||||
3-Year EPS without NRI Growth Rate | 11.8 | |||||
3-Year FCF Growth Rate | 18.6 | |||||
3-Year Book Growth Rate | 8.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.51 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.97 | |||||
9-Day RSI | 40.16 | |||||
14-Day RSI | 43.13 | |||||
3-1 Month Momentum % | 6.81 | |||||
6-1 Month Momentum % | -5.99 | |||||
12-1 Month Momentum % | 8.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.8 | |||||
Quick Ratio | 2.56 | |||||
Cash Ratio | 1.62 | |||||
Days Inventory | 436.77 | |||||
Days Sales Outstanding | 45.69 | |||||
Days Payable | 58.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.71 | |||||
Dividend Payout Ratio | 0.7 | |||||
3-Year Dividend Growth Rate | 17 | |||||
Forward Dividend Yield % | 3.71 | |||||
5-Year Yield-on-Cost % | 7.93 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 3.14 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.71 | |||||
Operating Margin % | 26.97 | |||||
Net Margin % | 21.68 | |||||
EBITDA Margin % | 30.4 | |||||
FCF Margin % | 24.69 | |||||
OCF Margin % | 24.69 | |||||
ROE % | 34.78 | |||||
ROA % | 25.42 | |||||
ROIC % | 35.14 | |||||
3-Year ROIIC % | 43.14 | |||||
ROC (Joel Greenblatt) % | 91.55 | |||||
ROCE % | 39.41 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 26.73 | |||||
Forward PE Ratio | 29.65 | |||||
PE Ratio without NRI | 26.73 | |||||
Shiller PE Ratio | 40.8 | |||||
Price-to-Owner-Earnings | 28.03 | |||||
PEG Ratio | 2.23 | |||||
PS Ratio | 5.79 | |||||
PB Ratio | 8.23 | |||||
Price-to-Tangible-Book | 10.31 | |||||
Price-to-Free-Cash-Flow | 23.14 | |||||
Price-to-Operating-Cash-Flow | 23.14 | |||||
EV-to-EBIT | 20.89 | |||||
EV-to-EBITDA | 18.25 | |||||
EV-to-Revenue | 5.55 | |||||
EV-to-FCF | 22.19 | |||||
Price-to-GF-Value | 0.88 | |||||
Price-to-Projected-FCF | 1.85 | |||||
Price-to-DCF (Earnings Based) | 1.29 | |||||
Price-to-DCF (FCF Based) | 0.78 | |||||
Price-to-Median-PS-Value | 0.84 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.44 | |||||
Price-to-Graham-Number | 3.5 | |||||
| Price-to-Net-Current-Asset-Value | 13.18 | |||||
| Price-to-Net-Cash | 124.38 | |||||
Earnings Yield (Greenblatt) % | 4.79 | |||||
FCF Yield % | 4.32 | |||||
Forward Rate of Return (Yacktman) % | 14.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medistim ASA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 62.344 | ||
| EPS (TTM) (€) | 0.739 | ||
| Beta | 0.9572 | ||
| 3-Year Sharpe Ratio | -0.04 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 40.51 | ||
| 14-Day RSI | 43.13 | ||
| 14-Day ATR (€) | 0.396051 | ||
| 20-Day SMA (€) | 20.4575 | ||
| 12-1 Month Momentum % | 8.8 | ||
| 52-Week Range (€) | 16.3 - 24.4 | ||
| Shares Outstanding (Mil) | 18.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medistim ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medistim ASA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-23 | In 109 days | ||
| Third quarter earnings results for 2026 | 2026-10-23 | In 109 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-19 | In 44 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 44 days | ||
| First quarter earnings conference call for 2026 | 2026-05-07 09:00 | 20.70 (+0.00%) | ||
| NOK 8.000000 Cash Dividend | 2026-05-07 | 20.70 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 20.70 (+0.00%) | ||
| General meeting for 2025 | 2026-05-06 10:00 | 20.50 (-2.38%) | ||
| Annual report for 2025 | 2026-04-14 | 20.50 (-0.97%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-27 09:00 | 18.65 (-2.61%) |
Show
Entries
Medistim ASA Frequently Asked Questions
What is Medistim ASA(FRA:MD1)'s stock price today?
The current price of FRA:MD1 is €19.90. The 52 week high of FRA:MD1 is €24.40 and 52 week low is €16.30.
When is next earnings date of Medistim ASA(FRA:MD1)?
The next earnings date of Medistim ASA(FRA:MD1) is 2026-08-19.
Does Medistim ASA(FRA:MD1) pay dividends? If so, how much?
The Dividend Yield %  of Medistim ASA(FRA:MD1) is 3.71% (As of Today), Highest Dividend Payout Ratio of Medistim ASA(FRA:MD1) was 0.79. The lowest was 0.58. And the median was 0.68. The  Forward Dividend Yield % of Medistim ASA(FRA:MD1) is 3.71%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Medistim ASA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers